Castle Biosciences (CSTL) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$357.3M

Revenue (quarter)

$103.5M

Revenue growth (year over year)

+20.14%

Gross profit (trailing twelve months)

$276.0M

Gross margin

77.26%

Net income (trailing twelve months)

−$19.4M

Net income (quarter)

−$2.1M

Net income growth (year over year)

−145.54%

Net margin

−5.43%

Return on equity

−4.20%

EPS (trailing twelve months)

−$0.64

Book value per share

$15.41

P/E (trailing twelve months)

—

Price to book

2.14

Debt to assets

16.24%

Payout ratio

—

Dividend yield

—

Company profile

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

• Is Castle Biosciences (CSTL) profitable?

  No. Castle Biosciences reported a net loss of $19.4M over the trailing twelve months.

• How much revenue does Castle Biosciences (CSTL) make?

  Castle Biosciences generated $357.3M in revenue over the trailing twelve months, up 20.14% year over year.

• How do I buy stock in Castle Biosciences (CSTL)?

  CSTL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.